Core Viewpoint - Zhejiang Yatai Pharmaceutical Co., Ltd. reported a significant decline in revenue while achieving a substantial increase in net profit for the first half of 2025, indicating a shift in financial performance dynamics [1][2]. Financial Performance - The company's operating revenue for the reporting period was CNY 152.07 million, a decrease of 31.48% compared to CNY 221.93 million in the same period last year [1]. - Net profit attributable to shareholders reached CNY 105.18 million, marking an increase of 1,820.97% from CNY 5.48 million in the previous year [1]. - The net profit after deducting non-recurring gains and losses was CNY -48.86 million, a decline of 524.31% compared to CNY -7.83 million in the same period last year [1]. - The basic earnings per share rose to CNY 0.14, up 1,300% from CNY 0.01 [1]. - The weighted average return on equity was 10.01%, compared to 0.94% in the previous year [1]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1.24 billion, down 11.35% from CNY 1.40 billion at the end of the previous year [1]. - The net assets attributable to shareholders were CNY 1.13 billion, an increase of 16.15% from CNY 972.18 million [2]. - The debt-to-asset ratio improved to 9.14% from 30.65% in the previous year [3]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 55,101 [2]. - Ningbo Fubon Holdings Group Co., Ltd. remained the controlling shareholder with an 11.99% stake [2]. Significant Events - The company completed the sale of its wholly-owned subsidiary, Shaoxing Xingya Pharmaceutical Co., Ltd., for a total consideration of CNY 175 million, which included the assumption of debts [4][5]. - The first payment of CNY 30 million was received on March 31, 2025, and the second payment of CNY 145 million was received on June 25, 2025 [5].

亚太药业: 关于亚药转债到期兑付及摘牌的公告 证券代码：002370 证券简称：亚太药业 公告编号：2025-023 债券代码：128062 债券简称：亚药转债 浙江亚太药业股份有限公司 关于"亚药转债"到期兑付及摘牌的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不 存在虚假记载、误导性陈述或者重大遗漏。 特别提示 息） （一）可转债发行上市情况 -1- 经中国证券监督管理委员会《关于核准浙江亚太药业股份有限公 司公开发行可转换公司债券的批复》 （证监许可〔2019〕225 号）核准， 浙江亚太药业股份有限公司（以下简称"公司"）于 2019 年 4 月 2 日 公开发行了 965 万张可转换公司债券，每张面值 100 元，发行总额 经深圳证券交易所"深证上〔2019〕224 号"文同意，公司 9.65 亿元可转换公司债券已于 2019 年 4 月 24 日在深圳证券交易所上市 交易，债券简称"亚药转债"，债券代码"128062" （二）可转债转股期限 根据相关法律法规和《浙江亚太药业股份有限公司公开发行可转 换公司债券募集说明书》 债"将被强制赎回；本次赎回完成后，"亚药转债"将在深圳证券交 ...

Core Viewpoint - The announcement serves as a reminder for the upcoming maturity and cessation of trading of the "YaYao Convertible Bonds" (亚药转债), emphasizing the importance for bondholders to convert their bonds into company shares before the deadline [1][2][5]. Group 1: Convertible Bond Issuance Details - The company issued 9.65 million convertible bonds at a face value of 100 RMB each, totaling 965 million RMB, which were listed on April 24, 2019 [1]. - The conversion price for the bonds is currently set at 3.00 RMB per share [5]. Group 2: Redemption and Trading Cessation - The bonds will be redeemed at 115% of their face value, amounting to 115 RMB per bond, including the last interest payment, within five trading days after maturity [2]. - The last trading day for the bonds is set for March 28, 2025, with trading ceasing on March 31, 2025 [5]. Group 3: Additional Information - The company will disclose further details regarding the maturity redemption and delisting of the bonds on designated information platforms [5].

证券代码：002370 证券简称：亚太药业 公告编号：2025-018 债券代码：128062 债券简称：亚药转债 浙江亚太药业股份有限公司 关于"亚药转债"即将到期及停止交易的第一次提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不 存在虚假记载、误导性陈述或者重大遗漏。 特别提示 1、"亚药转债"到期日和兑付登记日：2025 年 4 月 2 日 2、"亚药转债"到期兑付金额：115 元 /张（含税及最后一期利 息） 3、"亚药转债"最后交易日：2025 年 3 月 28 日 4、"亚药转债"停止交易日：2025 年 3 月 31 日 5、"亚药转债"最后转股日：2025 年 4 月 2 日 6、根据安排，截至 2025 年 4 月 2 日收市后仍未转股的"亚药转 债"将被强制赎回；本次赎回完成后，"亚药转债"将在深圳证券交 易所摘牌。特此提醒"亚药转债"持有人注意在转股期内转股。 7、在"亚药转债"停止交易后、转股期结束前，即 2025 年 3 月 31 日至 2025 年 4 月 2 日，"亚药转债"持有人仍可以依据约定的条 件，将"亚药转债"转换为公司股票，目前转股价格为 3.00 元 ...